Flaminia Pedretti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Flaminia Pedretti has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Violeta Serra
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
36 shared publications - Alba Llop-Guevara
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
35 shared publications - Alba Mas Malavila
Bioinformatics Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
35 shared publications - Andrea Herencia-Ropero
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
35 shared publications - Andreu Òdena
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
35 shared publications - Anna Pascual-Reguant
Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain
35 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Nature Communications
ISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair
The use of poly(ADP-ribose) polymerase inhibitors (PARPi) has proven largely successful in targeting BRCA1/2 -mutated tumours. However, the emergence of PARPi-resistant disease can reduce the efficacy of this treatment, posing significant challenges in the clinic. Here, we use multiple models of BRCA1 -/- cells and patient-derived xenografts (PDXs) that have been treated with PARPi until they no longer responded to the drug, to characterise genomic and transcriptomic alterations specific to PARPi resistance. We find that abrogation of TP53BP1 expression occurs spontaneously during prolonged PARPi treatment, alongside TP53BP1 genomic deletions and promoter methylation. Additionally, innate immune response genes, including ISG15 and factors of the ISGylation machinery are upregulated in PARPi-resistant cells and tumours. We demonstrate that ISG15 inhibition re-sensitises PARPi-resistant cells to the drug and, conversely, that ISG15 overexpression in BRCA1 -/- cells promotes PARPi resistance. Mechanistically, BRCA1 -/- PARPi-resistant cells rely on ISG15 for replication fork progression and restart of stalled forks and for DNA double-strand break (DSB) repair via homologous recombination (HR). Our results indicate that complex ISG15 interactions with DNA replication/repair factors can drive PARPi resistance in BRCA1-deficient cancer cells and that targeting ISG15 has the potential to overcome PARPi resistance.
- 12 November 2026
- Published by Springer Nature in Nature Communications
Open AccessISG15 promotes PARP inhibitor resistance in BRCA1-deficient cells by facilitating DNA replication and repair
The use of poly(ADP-ribose) polymerase inhibitors (PARPi) has proven largely successful in targeting BRCA1/2 -mutated tumours. However, the emergence of PARPi-resistant disease can reduce the efficacy of this treatment, posing significant challenges in the clinic. Here, we use multiple models of BRCA1 -/- cells and patient-derived xenografts (PDXs) that have been treated with PARPi until they no longer responded to the drug, to characterise genomic and transcriptomic alterations specific to PARPi resistance. We find that abrogation of TP53BP1 expression occurs spontaneously during prolonged PARPi treatment, alongside TP53BP1 genomic deletions and promoter methylation. Additionally, innate immune response genes, including ISG15 and factors of the ISGylation machinery are upregulated in PARPi-resistant cells and tumours. We demonstrate that ISG15 inhibition re-sensitises PARPi-resistant cells to the drug and, conversely, that ISG15 overexpression in BRCA1 -/- cells promotes PARPi resistance. Mechanistically, BRCA1 -/- PARPi-resistant cells rely on ISG15 for replication fork progression and restart of stalled forks and for DNA double-strand break (DSB) repair via homologous recombination (HR). Our results indicate that complex ISG15 interactions with DNA replication/repair factors can drive PARPi resistance in BRCA1-deficient cancer cells and that targeting ISG15 has the potential to overcome PARPi resistance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains